Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that
the Company has signed a second partner, Guangzhou Wondfo Biotech Co.,
Ltd. (Wondfo) in China to sell the Company’s diagnostic products,
expanding its strategic presence in this important global market.
“We have already seen great success in China with our first partner, O&D
Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac
products over the past few years”
“We have already seen great success in China with our first partner, O&D
Biotech Co., Ltd. China (O&D), selling our co-branded RAMP® cardiac
products over the past few years,” said S. Wayne Kay, Chief Executive
Officer. “In 2009, we recognized a significant portion of our revenues
from sales in China. We are pleased to sign the Wondfo agreement and
with representation by two strong partners in this region, we expect
sales in China to continue to make an important contribution to our
overall revenues.”
"China is an exciting and growing market and our continued international
market expansion is extremely important to our overall strategy. Wondfo
will be selling private label cardiac products, while O&D sells
co-branded RAMP® products on both the RAMP® and RAMP® 200 Readers."
Cognitive behavioral therapy shows promise for prolonged grief disorder